The U.S. drug regulator has unveiled a plan to dramatically speed up adverse event reporting. More: FDA rolls out daily updates to adverse event dashboard, plans to further 'streamline' system Source: fierce
read moreBeOne Medicines is monetizing its stake in Amgen’s first-in-class lung cancer drug Imdelltra for up to $950 million. More: BeOne bags 5M upfront in Royalty deal on Amgen's lung cancer drug Imdelltra Source: fierce
read moreOn a day when Bavarian Nordic reported booming sales and adjusted its 2025 guidance positively, its CEO said that a private equity buyout of the Danish company would provide the funding it needs to realize its potential. More: Bavarian Nordic
read moreTalks between the U.K. government and the biopharma industry have broken down over efforts to lower rebate rates under a national drug cost-containment scheme. More: UK pharma drug price talks break down as industry fails to lower discount rate Source:
read moreDespite boasting a new owner, the Indiana manufacturing plant that Novo Nordisk picked up as part of its parent company’s Catalent buyout last year continues to catch flak from the FDA. More: Novo plant acquired in Catalent buyout faces renewed
read moreU.S. pharma bounced back in Q2, and in this episode of “The Top Line,” Fierce Pharma’s Eric Sagonowsky and Kevin Dunleavy break down the numbers, company highlights and the rivalries behind the rebound. More: Big Pharma bounces back in Q2
read more© 1994 - 2026 B.M. Pharmaceuticals